Grant Funding
ARC funds basic, clinical and translational research across the full continuum of discovery.
We are committed to scientific rigor, transparency and long-term partnership with the research community.
Step 2: Full Proposal (by invitation)
Selected applicants will be invited to submit a full proposal, including scientific rationale, methods, timeline, budget, milestones, and data-sharing plans.
Eligibility
ARC welcomes LOIs from investigators and organizations working to advance understanding and treatment of AUTS2 syndrome, including:
Academic researchers
Clinician-scientists
Research institutes
Biotechnology companies
Cross-institutional collaborations
Applicants from any country are eligible.
Projects should demonstrate clear relevance to AUTS2 syndrome and have the potential to advance biological understanding, translational research, therapeutic development, or shared community resources.
Funding Opportunities
ARC currently offers:
Seed Grants — Up to $50,000
Support pilot studies, proof-of-concept research, and development of shared tools or resources.
Investigator Awards — Up to $100,000
Support projects that advance AUTS2 biology, therapeutic development, translational research, or clinical readiness.
Awards are typically one year in duration and may include up to 10% indirect costs.
Current Funding Cycle
ARC is accepting Letters of Intent (LOIs) on a rolling basis.
The first LOI review cycle closed on June 15, 2026. Investigators may continue to submit LOIs on a rolling basis. Selected applicants will be invited to submit a full proposal for funding consideration.
Apply for Funding
ARC uses a two-stage application process:
Step 1: Submit a Letter of Intent (LOI)
Researchers interested in funding should begin by submitting a brief Letter of Intent outlining the project, its relevance to AUTS2 syndrome, the proposed budget range, and the qualifications of the investigative team.
LOI templates and application materials are available below.